Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-04-29

FDA Approved: QELBREE — Supplemental Application (Supernus Pharmaceuticals, Inc)

View source ↗

Summary

FDA approved a supplemental application for Qelbree (viloxazine hydrochloride) from Supernus Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • QELBREE (viloxazine hydrochloride)

Snippet

SUPPL AP for QELBREE (VILOXAZINE HYDROCHLORIDE)